Cheryl Arrowsmith once again among Clarivate’s world’s highly cited researchers

Cheryl Arrowsmith, Chief Scientist of the Structural Genomics Consortium (SGC), Senior Scientist at the Princess Margaret Cancer Centre, and Professor at the Department of Medical Biophysics at the University of Toronto, has been honoured by Clarivate as one of the Highly Cited Researchers for 2023.

Among the 6,849 exceptional researchers acknowledged worldwide, this recognition underscores her contributions to the fields of structural and chemical biology, particularly in the context of chromatin and epigenetic regulatory factors for advancing our understanding of cancer and exploring novel avenues in drug discovery. Her published papers have been highly cited and ranked in the top one percent by citations for their respective fields and years of publication in the Web of Science citation index.

Cheryl’s prolific academic output includes over 300 research articles, a testament to her dedication to advancing scientific knowledge. Cheryl's influence has been acknowledged previously by Clarivate Analytics, recognized her among the world's top 1% of highly cited scientists in 2018 and 2019.

As the Chief Scientist of the SGC, Cheryl leads an international open science program in close collaboration with major pharmaceutical companies. This program is pivotal in the development and distribution of unencumbered chemical probes, which creates an environment conducive to discovering new medicines. Cheryl's leadership is a shining example of a commitment to open science, collaboration, and the advancement of knowledge for the greater good.

We wholeheartedly congratulate Cheryl on this well-deserved recognition. Visit Clarivate’s press release to learn more about 2023 Highly Cited Researchers.

glqxz9283 sfy39587stf02 mnesdcuix8